Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.
The conference’s abstract drop features ASC4First in its plenary session.
The company scraps its lead project and clears out its C-suite, but there was already a precedent.
Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.
An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.
The company dribbles out more data on IMA203, and the numbers head in the right direction.